Hellman Jordan Management Company’s Regeneron Pharmaceuticals REGN Stock Holding History

Hellman Jordan Management Company’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-20,000	Closed	-$6.26M	–	59
2019 Q2	$6.26M	Buy	+20,000	New	+$6.66M	8.55%	1
2019 Q1	–	Sell	-10,000	Closed	-$3.73M	–	60
2018 Q4	$3.73M	Sell	10,000 -25,000	-71%	-$9.15M	4.18%	8
2018 Q3	$14.1M	Sell	35,000 -15,000	-30%	-$5.71M	10.18%	3
2018 Q2	$17.2M	Buy	+50,000	New	+$15.6M	13.83%	1
2015 Q4	–	Sell	-20,000	Closed	-$9.3M	–	55
2015 Q3	$9.3M	Buy	+20,000	New	+$10.7M	2.3%	24
2015 Q1	–	Sell	-32,908	Closed	-$13.5M	–	60
2014 Q4	$13.5M	Buy	32,908 +6,986	+27%	+$2.75M	2.51%	13
2014 Q3	$9.35M	Buy	+25,922	New	+$8.69M	1.78%	26

Other funds holding REGN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Hellman Jordan Management Company's REGN Position: Q3 2019 in Review

Hellman Jordan Management Company sold out of Regeneron Pharmaceuticals (REGN) in Q3 2019, closing a stake of 20,000 shares — an estimated $6.26M sold.

Hellman Jordan Management Company first reported a position in REGN in Q3 2014 and held it in 7 quarters. The position peaked at $17.2M in Q2 2018. 633 funds tracked by Wall St. Rank hold REGN as of Q3 2019.

Hellman Jordan Management Company reported no remaining Regeneron Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Hellman Jordan Management Company sold 20,000 Regeneron Pharmaceuticals shares in Q3 2019, an estimated $6.26M.
Hellman Jordan Management Company first reported a position in Regeneron Pharmaceuticals in Q3 2014 and held it in 7 quarters.
Hellman Jordan Management Company's Regeneron Pharmaceuticals position peaked at $17.2M in Q2 2018.
633 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2019.

Based on Hellman Jordan Management Company's 13F filing for Q3 2019, filed 20 Dec 2019.